GO:1990830 cellular response to leukemia inhibitory factor: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990830 describes the cellular response to leukemia inhibitory factor (LIF), a pleiotropic cytokine that alters cell state, movement, secretion, enzyme production, and gene expression.
• LIF signals primarily through the LIF receptor (LIFR) and gp130, activating JAK-STAT3, MAPK, and PI3K pathways to control transcription and cell fate.
• The term is critical in stem cell pluripotency, embryo implantation, immune regulation, and tissue repair, and its dysregulation is linked to fibrosis, cancer, and retinal degeneration.
• LIF signaling is context-dependent: it can promote or inhibit cell growth and is hijacked by tumors to evade immune surveillance and support metastasis.
• Key genes include LIF, LIFR, IL6ST (gp130), STAT3, JAK1/2, and SOCS3, which are frequent targets for CRISPR knockout, knock-in, and point-mutation studies.
• EDITGENE provides CRISPR cell model services to dissect LIF signaling, including knockout, point mutation, knock-in, overexpression, and library screening.
Description
The Gene Ontology term GO:1990830, cellular response to leukemia inhibitory factor, defines any process that results in a change in state or activity of a cell as a result of a leukemia inhibitory factor (LIF) stimulus. LIF is a member of the interleukin-6 family of cytokines and acts through a heterodimeric receptor complex composed of LIFR and gp130 (IL6ST), triggering intracellular signaling cascades that include JAK-STAT3, MAPK/ERK, and PI3K/AKT. This term captures the full spectrum of cellular outcomes, from transcriptional reprogramming and altered secretion to changes in movement and enzyme production. Researchers study GO:1990830 because LIF signaling is a master regulator of stem cell pluripotency, embryo implantation, and immune cell function. In cancer, LIF is frequently overexpressed and promotes tumor progression, metastasis, and immune evasion, making it an attractive therapeutic target. In fibrosis, LIFR activation amplifies pathogenic fibroblast activation, and in retinal degeneration, LIF signaling modulates neuroprotection and gliosis. Understanding the precise molecular steps of this response is essential for developing targeted interventions. The term is also central to regenerative medicine, where LIF is used to maintain mouse embryonic stem cell pluripotency and to reprogram somatic cells. Because LIF responses are highly context-dependent, dissecting the underlying gene regulatory networks requires robust experimental models. This article provides a comprehensive overview of the ontology, mechanisms, key genes, disease links, and research methods for GO:1990830, with a focus on CRISPR-based approaches for functional validation.
cellular response to leukemia inhibitory factor At A Glance
| GO ID | GO:1990830 |
|---|---|
| GO term | cellular response to leukemia inhibitory factor |
| Ontology | biological_process |
| Synonym | cellular response to CDF; cellular response to cholinergic differentiation factor |
| Major function | Mediates cellular changes in movement, secretion, enzyme production, and gene expression in response to LIF stimulus |
| Primary receptor | LIFR and gp130 (IL6ST) heterodimer |
| Key downstream pathways | JAK-STAT3, MAPK/ERK, PI3K/AKT |
| Cellular outcomes | Pluripotency maintenance, differentiation, immune modulation, survival, migration |
| Disease relevance | Cancer, fibrosis, retinal degeneration, reproductive disorders |
What Is GO:1990830?
In our own words, GO:1990830 encompasses all cellular processes triggered when a cell encounters leukemia inhibitory factor (LIF). This includes the immediate sensing of LIF by its receptor, the activation of intracellular signaling cascades, and the resulting changes in gene expression, protein activity, metabolism, secretion, and cell behavior. The term is not limited to a single pathway but covers the integrated cellular response that can lead to differentiation, proliferation, survival, migration, or functional polarization depending on the cell type and context.
Why Is cellular response to leukemia inhibitory factor Important in Cell Biology?
GO:1990830 is important because LIF signaling is a central node in stem cell biology, immunology, and cancer. It governs the balance between self-renewal and differentiation in embryonic stem cells and is essential for embryo implantation. In the immune system, LIF modulates plasmacytoid dendritic cell function and licenses the transition from tissue to systemic immunity. In disease, aberrant LIF signaling drives lung fibrosis, promotes tumor progression and metastasis, and contributes to retinal degeneration. Thus, understanding this process provides insights into fundamental cell fate decisions and offers therapeutic opportunities.
• Maintains pluripotency and self-renewal in embryonic stem cells, a cornerstone of regenerative medicine.
• Regulates embryo implantation and reproductive success, with links to p53 and fertility.
• Controls immune cell development and function, including plasmacytoid dendritic cells and ILC2-mediated systemic immunity.
• Promotes pathogenic fibroblast activation in lung fibrosis, making it a target for antifibrotic therapies.
• Is hijacked by multiple cancer cell types to evade immune surveillance and support metastasis.
• Drives LIF-dependent lung cancer under glucose deprivation, linking metabolism to tumor growth.
• Modulates retinal degeneration and neuroprotective responses.
• Involves post-translational modifications that regulate STAT3 nuclear translocation.
• Provides a paradigm for cytokine signaling integration with other pathways (e.g., JAK-STAT, MAPK).
• Offers numerous targets for CRISPR-based functional genomics and drug discovery.
What Happens During cellular response to leukemia inhibitory factor?
LIF Binding and Receptor Activation
In simple terms: LIF docks onto its receptor on the cell surface, turning it on.
The cellular response begins when LIF binds to the LIF receptor (LIFR), which then recruits the shared signal-transducing subunit gp130 (IL6ST) to form a heterodimeric complex. This binding induces conformational changes that activate receptor-associated Janus kinases (JAK1, JAK2, TYK2), which phosphorylate tyrosine residues on the cytoplasmic tails of LIFR and gp130. These phosphotyrosines serve as docking sites for downstream signaling molecules, initiating the intracellular cascade.
JAK-STAT3 Pathway Activation
In simple terms: The signal travels to the nucleus to switch genes on or off.
The primary pathway activated by LIF is the JAK-STAT3 cascade. Phosphorylated receptor tyrosines recruit STAT3 via its SH2 domain, leading to JAK-mediated phosphorylation of STAT3 at Tyr705. Phosphorylated STAT3 forms dimers that translocate to the nucleus, where they bind DNA and regulate transcription of target genes involved in proliferation, differentiation, and survival. Asymmetric post-translational modifications of STAT3 dimers further regulate nuclear translocation, adding a layer of control.
MAPK/ERK and PI3K/AKT Signaling
In simple terms: Parallel signals help the cell grow, survive, or move.
In addition to STAT3, LIF activates the MAPK/ERK and PI3K/AKT pathways. The phosphorylated receptor complex recruits SHP2 and GRB2, leading to RAS activation and the ERK cascade, which regulates gene expression and cell cycle progression. PI3K/AKT signaling promotes survival and metabolism. These pathways integrate with STAT3 to shape the overall cellular response, which can vary by cell type and context.
Transcriptional Reprogramming and Cellular Outcomes
In simple terms: Genes get turned on or off, changing what the cell does.
Activated STAT3 and other transcription factors drive changes in gene expression that alter cell state. In embryonic stem cells, this maintains pluripotency; in immune cells, it modulates differentiation and function. In fibroblasts, LIF signaling amplifies pathogenic activation, contributing to fibrosis. In cancer cells, LIF-induced transcriptional programs promote survival, migration, and immune evasion. The specific outcome depends on the cellular context and the interplay with other signaling pathways.
Negative Feedback and Signal Termination
In simple terms: The cell puts the brakes on the signal to avoid overreaction.
To prevent excessive signaling, LIF activates negative feedback regulators such as SOCS3, which binds to the receptor and inhibits JAK activity. Protein tyrosine phosphatases (e.g., SHP1) also dephosphorylate JAKs and STAT3. This feedback is crucial for maintaining homeostasis; its dysregulation can lead to chronic inflammation or cancer.
Key Genes Involved in GO:1990830 cellular response to leukemia inhibitory factor
The following genes and proteins are central to the cellular response to leukemia inhibitory factor (GO:1990830), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LIF | Ligand that initiates signaling | Knockout/overexpression to study autocrine/paracrine effects; cancer and fibrosis models |
| LIFR | Ligand-binding receptor subunit | Knockout to block LIF signaling; mutations linked to fibrosis and cancer |
| IL6ST (gp130) | Signal-transducing receptor subunit | Knockout causes embryonic lethality; point mutations to dissect JAK binding |
| JAK1 | Receptor-associated kinase | Knockout/point mutation to study phosphorylation of STAT3 |
| JAK2 | Receptor-associated kinase | Knockout to assess redundancy with JAK1; role in hematopoiesis |
| STAT3 | Transcription factor | Knockout/knock-in of phospho-mutants to study nuclear translocation and gene regulation |
| SOCS3 | Negative feedback regulator | Overexpression to suppress LIF signaling; knockout to enhance response |
| SHP2 (PTPN11) | Adaptor/phosphatase linking to MAPK | Point mutations to study ERK activation |
| GRB2 | Adaptor for RAS-MAPK pathway | Knockout to disrupt MAPK signaling |
| PIK3CA | PI3K catalytic subunit | Overexpression/knockout to study AKT survival signaling |
| AKT1 | Serine/threonine kinase | Knockout to assess survival and metabolism |
| MAPK1 (ERK2) | Kinase in MAPK cascade | Knockout to study proliferation and differentiation |
| p53 (TP53) | Tumor suppressor and regulator of reproduction | Knockout to study LIF cross-talk in implantation |
| ILC2 markers (e.g., GATA3) | Immune cell transcription factor | Knockout to study ILC2-derived LIF in systemic immunity |
| pDC markers (e.g., IRF7) | Plasmacytoid dendritic cell factor | Knockout to study LIF-mediated inhibition |
| Galectin-3 (LGALS3) | LIF co-released factor in cancer | Knockout to study neural hijacking |
| CDH1 (E-cadherin) | Cell adhesion molecule | Knockout to study LIF-induced EMT in cancer |
| VIM (Vimentin) | Mesenchymal marker | Overexpression to study LIF-driven metastasis |
How Is cellular response to leukemia inhibitory factor Regulated?
The cellular response to LIF is tightly regulated at multiple levels. Negative feedback via SOCS3 and SHP1 terminates signaling. Post-translational modifications of STAT3, such as asymmetric phosphorylation, control nuclear translocation. Cross-talk with other pathways (e.g., p53, mTOR) modulates the outcome. In cancer, glucose deprivation can enhance LIF-dependent signaling, linking metabolism to gene regulation. Additionally, LIF expression itself is regulated by inflammatory cytokines and transcription factors, creating autocrine loops in fibrosis and tumors.
cellular response to leukemia inhibitory factor and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LIFR | Lung fibrosis | LIFR knockout mice or human lung fibroblast CRISPR KO |
| LIF | Cancer (lung, pancreatic, etc.) | LIF knockout cancer cell lines; xenograft models |
| STAT3 | Cancer, immune disorders | STAT3 knockout or phospho-mutant knock-in cells |
| SOCS3 | Inflammatory diseases | SOCS3 overexpression or knockout in immune cells |
| p53 | Reproductive disorders | p53 knockout mice; uterine LIF expression studies |
LIF Signaling in Cancer
LIF is overexpressed in multiple cancers and promotes tumor progression, metastasis, and immune evasion. Cancer cells release LIF and Galectin-3 to hijack neural signals, facilitating perineural invasion. In lung cancer, glucose deprivation drives LIF-dependent growth, linking metabolic stress to tumor survival. Targeting LIF or its receptor with CRISPR knockout or inhibitory antibodies reduces tumor growth in preclinical models.
LIF in Fibrosis
LIF receptor signaling amplifies pathogenic activation of fibroblasts in lung fibrosis. LIFR is upregulated in fibrotic lungs, and its activation promotes collagen deposition and tissue remodeling. Knockout of LIFR or LIF in mouse models attenuates fibrosis, suggesting that targeting this pathway could be therapeutic.
LIF in Retinal Degeneration
In degenerating retinas, LIF signaling modulates neuroprotective and gliotic responses. LIF is upregulated after retinal injury and can promote Müller glia dedifferentiation and photoreceptor survival. However, chronic LIF activation may contribute to glial scarring. Understanding the balance is key for developing regenerative therapies.
LIF in Immune Regulation and Reproduction
LIF inhibits plasmacytoid dendritic cell function and development, affecting antiviral immunity. ILC2-derived LIF licenses the transition from tissue to systemic immunity, highlighting its role in immune cell trafficking. In reproduction, LIF is essential for embryo implantation, and p53 regulates LIF expression in the uterus. Dysregulation can lead to infertility or pregnancy loss.
From cellular response to leukemia inhibitory factor-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LIFR mediate fibroblast activation in fibrosis? | LIFR knockout in human lung fibroblasts or conditional KO mice |
| How does LIF promote cancer metastasis? | LIF knockout cancer cell lines in orthotopic models |
| What is the role of STAT3 phosphorylation in nuclear translocation? | STAT3 point-mutation knock-in (Y705F) cells |
| How does LIF inhibit pDC function? | LIFR knockout in primary pDCs or pDC-like cell lines |
| Does glucose deprivation enhance LIF signaling? | LIF overexpression or knockout in lung cancer cells under low glucose |
| What is the role of LIF in retinal degeneration? | LIF knockout or LIFR knockout in retinal explants or mouse models |
How to Study the cellular response to leukemia inhibitory factor Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify LIF-induced transcriptional programs |
| Phosphoproteomics | Phosphorylation events | Map JAK-STAT and MAPK activation |
| Immunofluorescence | STAT3 nuclear translocation | Study post-translational modifications |
| CRISPR knockout screens | Gene essentiality or modifiers | Discover regulators of LIF response |
| Western blot | Protein levels and phosphorylation | Validate signaling pathways |
| Flow cytometry | Immune cell differentiation and function | Assess LIF effects on pDCs or ILC2s |
| Reporter assays | STAT3 transcriptional activity | Screen for inhibitors or mutations |
| Co-immunoprecipitation | Protein-protein interactions | Study receptor complex assembly |
Transcriptomic Analysis (RNA-seq)
RNA sequencing after LIF stimulation reveals global changes in gene expression, identifying STAT3 target genes and context-specific transcriptional programs. Comparing wild-type and CRISPR knockout cells (e.g., STAT3 KO) pinpoints direct versus indirect effects.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics quantifies LIF-induced changes in protein abundance and phosphorylation, uncovering signaling dynamics and feedback loops. Phosphoproteomics can map JAK-STAT and MAPK activation kinetics.
Imaging and Nuclear Translocation Assays
Fluorescence microscopy with STAT3-GFP fusion proteins or immunofluorescence for phosphorylated STAT3 visualizes nuclear translocation in real time. This is useful for studying post-translational modifications and mutants.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens in LIF-treated cells identify genes that modulate the response, including novel regulators of pluripotency, immune evasion, or fibrosis. These screens can be combined with RNA-seq readouts.
How CRISPR Can Be Used to Study GO:1990830 cellular response to leukemia inhibitory factor
Knockout
CRISPR knockout of LIF, LIFR, IL6ST, JAK1/2, or STAT3 abolishes or attenuates the cellular response to LIF, providing a clean background to study downstream effects. Knockout cell lines are essential for validating specificity of inhibitors and for identifying compensatory pathways.
Point Mutation
Point mutations (e.g., STAT3 Y705F, JAK2 V617F) can be introduced via CRISPR knock-in to dissect phosphorylation-dependent functions and disease-associated variants. These models help distinguish between signaling branches and reveal mechanisms of drug resistance.
Knock-in
Knock-in of tagged proteins (e.g., STAT3-GFP, LIFR-HA) allows real-time imaging and biochemical purification of endogenous complexes. Knock-in of reporter genes (e.g., STAT3-luciferase) enables high-throughput screening.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of LIF, LIFR, or constitutively active STAT3 can amplify the response, useful for studying gain-of-function in cancer and fibrosis. Overexpression models help identify downstream targets and resistance mechanisms.
How EDITGENE Supports cellular response to leukemia inhibitory factor Research
Researchers studying cellular response to leukemia inhibitory factor-related genes often need to determine whether a candidate gene is causally involved in LIF signaling, immune modulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for cellular response to leukemia inhibitory factor research.
Frequently Asked Questions About cellular response to leukemia inhibitory factor
What is GO:1990830?
GO:1990830 is the Gene Ontology term for cellular response to leukemia inhibitory factor, describing all cellular changes triggered by LIF stimulus.
What genes are involved in cellular response to leukemia inhibitory factor?
Key genes include LIF, LIFR, IL6ST (gp130), JAK1, JAK2, STAT3, SOCS3, and downstream effectors like MAPK1 and AKT1.
What diseases are associated with LIF signaling?
LIF signaling is linked to cancer, lung fibrosis, retinal degeneration, reproductive disorders, and immune dysregulation.
How does LIF activate STAT3?
LIF binding to LIFR/gp130 activates JAK kinases, which phosphorylate STAT3 at Tyr705, leading to dimerization and nuclear translocation.
What is the role of LIF in stem cells?
LIF maintains pluripotency and self-renewal in mouse embryonic stem cells and is used in reprogramming.
Can CRISPR be used to study LIF signaling?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect LIF pathway components and their functions.
What are the synonyms for GO:1990830?
The synonyms are cellular response to CDF and cellular response to cholinergic differentiation factor.
How is LIF signaling regulated?
It is regulated by negative feedback via SOCS3 and SHP1, post-translational modifications of STAT3, and cross-talk with other pathways.
What experimental models are used to study LIF response?
Common models include knockout mice, CRISPR-edited cell lines, and primary immune cells treated with LIF.
What methods measure LIF-induced gene expression?
RNA-seq, phosphoproteomics, and reporter assays are widely used to measure transcriptional and signaling changes.
Conclusion
GO:1990830 cellular response to leukemia inhibitory factor is a fundamental biological process that integrates cytokine signaling with cell fate, immunity, and disease. Its dysregulation contributes to cancer, fibrosis, and reproductive disorders, making it a prime target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the molecular players and validating drug targets. EDITGENE offers comprehensive services to accelerate research in this field, from knockout and knock-in cell lines to library screening and bioinformatics.
References
- 1. Nguyen HN et al.. 2024. Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.. Proc Natl Acad Sci U S A 121(50):e2401899121 PMID: 39636853
- 2. Gogoi M et al.. 2024. ILC2-derived LIF licences progress from tissue to systemic immunity.. Nature 632(8026):885-892 PMID: 39112698
- 3. Kang HJ et al.. 2018. p53 and reproduction.. Fertil Steril 109(1):39-43 PMID: 29307398
- 4. Xu Q et al.. 2024. Multiple cancer cell types release LIF and Gal3 to hijack neural signals.. Cell Res 34(5):345-354 PMID: 38467743
- 5. Diallo M et al.. 2024. Asymmetric post-translational modifications regulate the nuclear translocation of STAT3 homodimers in response to leukemia inhibitory factor.. Cell Oncol (Dordr) 47(3):1065-1070 PMID: 38150153
- 6. Sesti-Costa R et al.. 2020. Leukemia Inhibitory Factor Inhibits Plasmacytoid Dendritic Cell Function and Development.. J Immunol 204(8):2257-2268 PMID: 32169845
- 7. Luciano-Mateo F et al.. 2026. Glucose deprivation drives LIF-dependent lung cancer.. Nat Metab 8(2):410-430 PMID: 41617990
- 8. Agca C et al.. 2014. Leukemia inhibitory factor signaling in degenerating retinas.. Adv Exp Med Biol 801:389-94 PMID: 24664722
